10% Discount on Non-Alcoholic Steatohepatitis Drugs - Valid Upto 7th June 2016.

Bharat Book Bureau provides the report; on “Non-Alcoholic SteatoHepatitis Analysis of Disease Prevalence, Drugs in development” This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. https://www.bharatbook.com/healthcare-market-research-reports-420132/non-alcoholic-steatohepatitis-disease-prevalence-drugs.html

09th April, 2016- Mumbai, India: Bharatbook.com announces a report on “Non-Alcoholic SteatoHepatitis Analysis of Disease Prevalence, Drugs in development” This Report In Japan, the prevalence of NASH is rising although the population is not typically overweight.

Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy. US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH.

NASH is the progressive form of Non-Alcoholic Fatty Liver Disease – NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patient's liver to harden and failure to work properly. It is estimated that NASH affects 2 to 5% of the US population. Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease. Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty. In Japan, the prevalence of NASH is rising although the population is not typically overweight. Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities.

As per the US Association of Liver Disease,...